{
  "FullStudy":{
    "Rank":217623,
    "Study":{
      "ProtocolSection":{
        "IdentificationModule":{
          "NCTId":"NCT01518985",
          "OrgStudyIdInfo":{
            "OrgStudyId":"SPIRI-120"
          },
          "Organization":{
            "OrgFullName":"Stealth BioTherapeutics Inc.",
            "OrgClass":"INDUSTRY"
          },
          "BriefTitle":"The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking",
          "OfficialTitle":"A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking"
        },
        "StatusModule":{
          "StatusVerifiedDate":"April 2012",
          "OverallStatus":"Completed",
          "ExpandedAccessInfo":{
            "HasExpandedAccess":"No"
          },
          "StartDateStruct":{
            "StartDate":"January 2012"
          },
          "PrimaryCompletionDateStruct":{
            "PrimaryCompletionDate":"March 2012",
            "PrimaryCompletionDateType":"Actual"
          },
          "CompletionDateStruct":{
            "CompletionDate":"March 2012",
            "CompletionDateType":"Actual"
          },
          "StudyFirstSubmitDate":"January 23, 2012",
          "StudyFirstSubmitQCDate":"January 25, 2012",
          "StudyFirstPostDateStruct":{
            "StudyFirstPostDate":"January 26, 2012",
            "StudyFirstPostDateType":"Estimate"
          },
          "LastUpdateSubmitDate":"April 17, 2012",
          "LastUpdatePostDateStruct":{
            "LastUpdatePostDate":"April 19, 2012",
            "LastUpdatePostDateType":"Estimate"
          }
        },
        "SponsorCollaboratorsModule":{
          "ResponsibleParty":{
            "ResponsiblePartyType":"Sponsor"
          },
          "LeadSponsor":{
            "LeadSponsorName":"Stealth BioTherapeutics Inc.",
            "LeadSponsorClass":"INDUSTRY"
          }
        },
        "OversightModule":{
          "OversightHasDMC":"No"
        },
        "DescriptionModule":{
          "BriefSummary":"This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette."
        },
        "ConditionsModule":{
          "ConditionList":{
            "Condition":[
              "Healthy Volunteers"
            ]
          }
        },
        "DesignModule":{
          "StudyType":"Interventional",
          "PhaseList":{
            "Phase":[
              "Phase 1"
            ]
          },
          "DesignInfo":{
            "DesignAllocation":"Randomized",
            "DesignInterventionModel":"Crossover Assignment",
            "DesignPrimaryPurpose":"Basic Science",
            "DesignMaskingInfo":{
              "DesignMasking":"Quadruple",
              "DesignWhoMaskedList":{
                "DesignWhoMasked":[
                  "Participant",
                  "Care Provider",
                  "Investigator",
                  "Outcomes Assessor"
                ]
              }
            }
          },
          "EnrollmentInfo":{
            "EnrollmentCount":"6",
            "EnrollmentType":"Actual"
          }
        },
        "ArmsInterventionsModule":{
          "ArmGroupList":{
            "ArmGroup":[
              {
                "ArmGroupLabel":"Placebo",
                "ArmGroupType":"Placebo Comparator",
                "ArmGroupDescription":"Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start",
                "ArmGroupInterventionList":{
                  "ArmGroupInterventionName":[
                    "Drug: Sterile saline (0.9%)",
                    "Other: Cigarette smoking"
                  ]
                }
              },{
                "ArmGroupLabel":"Bendavia",
                "ArmGroupType":"Experimental",
                "ArmGroupDescription":"Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start",
                "ArmGroupInterventionList":{
                  "ArmGroupInterventionName":[
                    "Drug: Bendavia",
                    "Other: Cigarette smoking"
                  ]
                }
              }
            ]
          },
          "InterventionList":{
            "Intervention":[
              {
                "InterventionType":"Drug",
                "InterventionName":"Bendavia",
                "InterventionDescription":"Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "Bendavia"
                  ]
                }
              },{
                "InterventionType":"Drug",
                "InterventionName":"Sterile saline (0.9%)",
                "InterventionDescription":"Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "Placebo"
                  ]
                }
              },{
                "InterventionType":"Other",
                "InterventionName":"Cigarette smoking",
                "InterventionDescription":"One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "Bendavia",
                    "Placebo"
                  ]
                }
              }
            ]
          }
        },
        "OutcomesModule":{
          "PrimaryOutcomeList":{
            "PrimaryOutcome":[
              {
                "PrimaryOutcomeMeasure":"Analysis of variance (ANOVA) between group mean endothelial function (EndoPAT Index) following smoking a single cigarette with and without Bendavia",
                "PrimaryOutcomeDescription":"Endothelial function will be determined using EndoPAT 2000 (Itamar Medical Ltd) prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of endothelial function (EndoPAT Index) between placebo and active study drug within a subject will be performed.\n\nEndoPAT quantifies the endothelium-mediated changes in vascular tone. A post-occlusion to pre-occlusion ratio is calculated providing the EndoPAT index.",
                "PrimaryOutcomeTimeFrame":"Baseline, +30, +60, +90 minutes post-study-drug administration start"
              }
            ]
          },
          "SecondaryOutcomeList":{
            "SecondaryOutcome":[
              {
                "SecondaryOutcomeMeasure":"Anova between group mean inflammatory laboratory marker (hs-CRP; mg/L) after smoking one cigarette with and without Bendavia",
                "SecondaryOutcomeDescription":"hs-CRP will be evaluated prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of hs-CRP levels between placebo and active study drug within a subject will be performed.",
                "SecondaryOutcomeTimeFrame":"Baseline to 24 hours post-study-drug administration"
              },{
                "SecondaryOutcomeMeasure":"ANOVA between group means of urinary 8-isoprostane (ng/mg of creatinine) after smoking one cigarette with and without Bendavia",
                "SecondaryOutcomeDescription":"8-isoprostane will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.",
                "SecondaryOutcomeTimeFrame":"Baseline to 48 hours post-study-drug administration"
              },{
                "SecondaryOutcomeMeasure":"Number adverse events with and without Bendavia",
                "SecondaryOutcomeDescription":"Adverse events will be tabulated by treatment group. No statistical analysis will be preformed.",
                "SecondaryOutcomeTimeFrame":"Baseline to Study Day 10"
              },{
                "SecondaryOutcomeMeasure":"Assessment of Bendavia exposure measured by area Under the Curve (AUC; ng*hr/mL)",
                "SecondaryOutcomeDescription":"Bendavia levels will be measured and pharmacokinetic parameters reported.",
                "SecondaryOutcomeTimeFrame":"Baseline to 48 hours post-study-drug administration"
              },{
                "SecondaryOutcomeMeasure":"ANOVA between group means of urinary 8-hydroxy-2'-deoxyguanosine (pg/mL) after smoking one cigarette with and without Bendavia",
                "SecondaryOutcomeDescription":"8-hydroxy-2'-deoxyguanosine will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.",
                "SecondaryOutcomeTimeFrame":"Baseline to 48 hours post-study-drug administration"
              }
            ]
          }
        },
        "EligibilityModule":{
          "EligibilityCriteria":"Inclusion Criteria:\n\n- Healthy adult male smokers between 18 and 65 years of age with signed informed consent\n\nExclusion Criteria:\n\nSerum sodium level below the lower limit of sites' clinical laboratory normal range at screening, D-1 and 6\nCholesterol level ≥ 240 mg/dL\nHypertension (blood pressure SBP > 140, DBP > 90 mmHg)\nBody mass index < 18 or > 32 kg/m2,\nCreatinine clearance calculated by the Cockcroft and Gault method calculated to be < 90 mL/min,\nAdditional laboratory abnormalities determined as clinically significant by the Principal Investigator at laboratory screening\nClinically significant abnormalities on physical examination,\nHistory or evidence of renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) system dysfunction,\nHistory of seizures or history of epilepsy,\nHistory of serious (Principal Investigator judgment) mental illness,\nReceipt of investigational medicinal product within 30 days prior to the planned date of study drug administration,\nPositive serology for human immunodeficiency virus type 1 or 2, or hepatitis B surface antigen,\nFever > 37.5°C at the time of planned dosing,\nSuspicion, or recent history, of alcohol or substance abuse,\nDonated blood or blood products within the past 30 days,\nEmployee or family member of the investigational site,\nSubjects who are either unwilling to agree to refrain from use or found to be using Nicotine (or nicotine products) including cigarettes from 12 hours prior to start of each study drug infusion through to the completion of endothelial function testing, Alcohol, Caffeine, Xanthine-containing food or beverages and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods, Supplementary antioxidant vitamins from 7 days prior to dosing and throughout the confinement periods, Prescription medications from 14 days prior to and 7 days post treatment\nSubjects having previous exposure to Bendavia.",
          "HealthyVolunteers":"Accepts Healthy Volunteers",
          "Gender":"Male",
          "MinimumAge":"18 Years",
          "MaximumAge":"65 Years",
          "StdAgeList":{
            "StdAge":[
              "Adult",
              "Older Adult"
            ]
          }
        },
        "ContactsLocationsModule":{
          "OverallOfficialList":{
            "OverallOfficial":[
              {
                "OverallOfficialName":"Kenneth C Lasseter, MD",
                "OverallOfficialAffiliation":"Clinical Pharmacology of Miami",
                "OverallOfficialRole":"Principal Investigator"
              },{
                "OverallOfficialName":"Richard Straube, MD",
                "OverallOfficialAffiliation":"Stealth Peptides",
                "OverallOfficialRole":"Study Director"
              }
            ]
          },
          "LocationList":{
            "Location":[
              {
                "LocationFacility":"Clinical Pharmaology of Miami",
                "LocationCity":"Miami",
                "LocationState":"Florida",
                "LocationZip":"33014-3616",
                "LocationCountry":"United States"
              }
            ]
          }
        }
      },
      "DerivedSection":{
        "MiscInfoModule":{
          "VersionHolder":"April 22, 2020"
        }
      }
    }
  }
}